Font size
WorksheetsLipids and ASCVD
Total questions: 20
Worksheet time: 30mins
What are the two sources of lipids?
exogenous
endogenous
indigenous
cytoplasmic
Endogenous lipids are produced in what part of the body?
kidneys
heart
liver
gall bladder
Defined as acute coronary syndromes, a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin.
Atherosclerosis
Cardiometabolic syndrome
Atherosclerotic Cardiovascular Disease
Dyslipidemia
Defined as chronic, progressive disease characterized by the accumulation of fatty and fibrous material in the innermost layer of arteries that results in the formation of atherosclerotic plaques.
Hyperlipidemia
Myocardial infarction
Atherosclerosis
Heart Failure
What transports lipids into the tissues?
lipoproteins
Apolipoproteins
chylomicrons
VLDL
What is the most abundant atherogenic lipoprotein?
Chylomicron
VLDL
IDL
LDL
Long term exposure to LDL-C is a key predictor of ASCVD risk.
True
False
Reducing LDL-C can slow the progression of plaque volume but does not regress plaque volume.
True
False
In individuals without established ASCVD but at high risk of an ASCVD event, low or moderate risk factor modification is a priority
True
False
What is the indication of Sybrava?
Adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia
For NYHA Class II - IV adult patients
Adults with controlled LDL-C
What is the recommended dose of Sybrava?
The recommended dose is 284 mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months.
The recommended dose is 300 mg administered as a single intramuscular injection: initially, again at 3 months, followed by every 6 months
The recommended dose is 284 mg administered as a single subcutaneous injection: initially, again at 6 months, followed by every 9 months
The recommended dose is 300 mg administered as a single intradermal injection: initially, again at 6 months, followed by every 6 months.
Dose adjustment is required for patients with mild to moderate hepatic impairment.
True
False
For patients on dialysis taking Sybrava, hemodialysis should not be performed for at least how many hours?
for at least 24 hrs
for at least 48hours
for at least 72 hours
should never be performed
What is the most common adverse event of Sybrava?
pain at the injection site
hyperuricemia
hypotension
dizziness
Which of the following describes inclisiran?
double stranded siRNA
PCKS9 inhibitor
HMG-CoA reductase inhibitors
Galnac conjugate
Following a single subcutaneous administration of 284 mg of inclisiran, LDL-C reduction was apparent within how many days post-dose?
7 days
10 days
14 days
28 days
Inclisiran binds with what receptor via 3x-GAlNac?
LDL receptor
Apoprotein receptors
asialoglycoprotein receptors
argonaute
As inclisiran enters the cytoplasm, it is loaded onto what type of complex?
DNA induced silencing complex
LDL induced silencing complex
RNA induced silencing complex
mRNA induced complex
What cleaves the passenger strand and separates it to the guide strand as inclisiran is loaded onto the RISC?
Arganine
Argonaute-2
PCSK9
mRNA
Inclisiran prevents the synthesis of PCKS9 resulting to more LDL-C receptors and increased uptake of LDL.
True
False
